volume 16 issue 6 pages 9428-9441

Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes

Chao Ji 1, 2
Maoru Zhao 1, 3
Chengyan Wang 1, 3
Ruixue Liu 1
Shuang Zhu 1, 3
Xinghua Dong 1
Chunjian Su 2
Zhanjun Gu 1, 3
Publication typeJournal Article
Publication date2022-06-06
scimago Q1
wos Q1
SJR4.497
CiteScore24.2
Impact factor16.0
ISSN19360851, 1936086X
General Physics and Astronomy
General Materials Science
General Engineering
Abstract
Metastasis of breast carcinoma is commonly realized through lymphatic circulation, which seriously threatens the lives of breast cancer patients. Therefore, efficient therapy for both primary tumor and metastatic sentinel lymph nodes (SLNs) is highly desired to inhibit cancer growth and metastasis. During breast cancer treatment, radiotherapy (RT) is a common clinical method. However, the efficacy of RT is decreased by the radioresistance to a hypoxic microenvironment and inevitable side effects for healthy issues at high radiation doses. Considering the above-mentioned, we provide high biocompatible poly(vinylpyrrolidone) coated Ta nanoparticles (Ta@PVP NPs) for photothermal therapy (PTT) assisted RT for primary tumor and metastatic SLNs. On the one hand, for primary tumor treatment, Ta@PVP NPs with a high X-ray mass attenuation coefficient (4.30 cm2/kg at 100 keV) can deposit high radiation doses within tumors. On the other hand, for metastatic SLNs treatment, the effective delivery of Ta@PVP NPs from the primary tumor into SLNs is monitored by computed tomography and photoacoustic imaging, which greatly benefit the prognosis and treatment for metastatic SLNs. Moreover, Ta@PVP NPs-mediated PTT could enhance the RT effect, and immunogenic cell death caused by RT/PTT could induce an immune response to improve the therapeutic effect of metastatic SLNs. This study not only explores the potential of Ta@PVP NPs as effective radiosensitizers and photothermal agents for combined RT and PTT but also offers an efficient strategy to cure both primary tumor and metastatic SLNs in breast carcinoma.
Found 
Found 

Top-30

Journals

1
2
3
4
5
6
7
ACS applied materials & interfaces
7 publications, 9.86%
Journal of Nanobiotechnology
5 publications, 7.04%
Chemical Engineering Journal
5 publications, 7.04%
Advanced healthcare materials
5 publications, 7.04%
ACS Nano
4 publications, 5.63%
Coordination Chemistry Reviews
4 publications, 5.63%
Small
3 publications, 4.23%
Advanced Science
2 publications, 2.82%
Materials and Design
2 publications, 2.82%
Journal of Colloid and Interface Science
2 publications, 2.82%
Chemical Society Reviews
2 publications, 2.82%
Acta Biomaterialia
2 publications, 2.82%
Nano Letters
1 publication, 1.41%
Diagnostics
1 publication, 1.41%
Frontiers in Oncology
1 publication, 1.41%
Journal of Materials Chemistry B
1 publication, 1.41%
Analytical Chemistry
1 publication, 1.41%
Biochemical and Biophysical Research Communications
1 publication, 1.41%
Chinese Journal of Chemistry
1 publication, 1.41%
International Journal of Nanomedicine
1 publication, 1.41%
Vaccines
1 publication, 1.41%
ACS Materials Letters
1 publication, 1.41%
Chemical Reviews
1 publication, 1.41%
ACS Applied Nano Materials
1 publication, 1.41%
Advanced Drug Delivery Reviews
1 publication, 1.41%
MedComm – Oncology
1 publication, 1.41%
Nano Today
1 publication, 1.41%
Rare Metals
1 publication, 1.41%
Tungsten
1 publication, 1.41%
Discover Materials
1 publication, 1.41%
1
2
3
4
5
6
7

Publishers

5
10
15
20
25
Elsevier
22 publications, 30.99%
American Chemical Society (ACS)
16 publications, 22.54%
Wiley
15 publications, 21.13%
Springer Nature
7 publications, 9.86%
Royal Society of Chemistry (RSC)
4 publications, 5.63%
MDPI
3 publications, 4.23%
Frontiers Media S.A.
2 publications, 2.82%
Taylor & Francis
1 publication, 1.41%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
1 publication, 1.41%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
71
Share
Cite this
GOST |
Cite this
GOST Copy
Ji C. et al. Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes // ACS Nano. 2022. Vol. 16. No. 6. pp. 9428-9441.
GOST all authors (up to 50) Copy
Ji C., Zhao M., Wang C., Liu R., Zhu S., Dong X., Su C., Gu Z. Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes // ACS Nano. 2022. Vol. 16. No. 6. pp. 9428-9441.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1021/acsnano.2c02314
UR - https://doi.org/10.1021/acsnano.2c02314
TI - Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes
T2 - ACS Nano
AU - Ji, Chao
AU - Zhao, Maoru
AU - Wang, Chengyan
AU - Liu, Ruixue
AU - Zhu, Shuang
AU - Dong, Xinghua
AU - Su, Chunjian
AU - Gu, Zhanjun
PY - 2022
DA - 2022/06/06
PB - American Chemical Society (ACS)
SP - 9428-9441
IS - 6
VL - 16
PMID - 35666259
SN - 1936-0851
SN - 1936-086X
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Ji,
author = {Chao Ji and Maoru Zhao and Chengyan Wang and Ruixue Liu and Shuang Zhu and Xinghua Dong and Chunjian Su and Zhanjun Gu},
title = {Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes},
journal = {ACS Nano},
year = {2022},
volume = {16},
publisher = {American Chemical Society (ACS)},
month = {jun},
url = {https://doi.org/10.1021/acsnano.2c02314},
number = {6},
pages = {9428--9441},
doi = {10.1021/acsnano.2c02314}
}
MLA
Cite this
MLA Copy
Ji, Chao, et al. “Biocompatible Tantalum Nanoparticles as Radiosensitizers for Enhancing Therapy Efficacy in Primary Tumor and Metastatic Sentinel Lymph Nodes.” ACS Nano, vol. 16, no. 6, Jun. 2022, pp. 9428-9441. https://doi.org/10.1021/acsnano.2c02314.